Pionyr Immunotherapeutics Inc, a developer of antibody therapeutics, has raised $62 million in Series B funding. New Enterprise Associates led the round with participation from other investors that included Sofinnova Ventures, Vida Ventures, OrbiMed, SV Health Investors, Osage University Partners and Mission Bay Ventures.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: